Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection

2016162 citationsJournal Articlegreen Open Access

Authors

Robin K. Avery · Johns Hopkins University

Ravit Arav‐Boger · Development Fund

Kieren A. Marr · Development Fund

Edward S. Kraus · Development Fund

Shmuel Shoham · Development Fund

Laura Lees · Development Fund

Brandon Trollinger ·

Abstract

Outcomes of existing treatment for ganciclovir-resistant or refractory CMV are suboptimal, in terms of virologic clearance, renal dysfunction, and mortality. These data should provide background information for future clinical trials of newer antiviral agents.

Topics & Keywords

Cytomegalovirus and herpesvirus research Herpesvirus Infections and Treatments Polyomavirus and related diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Transplantation

Volume 100, Issue 10, pp. e74-e80

DOI: 10.1097/tp.0000000000001418

Field-Weighted Citation Impact: 9.96